Photo Credit: wildpixel
The following is a summary of “Role of T cell metabolism in brain tumor development: a genetic and metabolic approach,” published in the January 2025 issue of Neurology by Yang et al.
Malignant brain tumors are lethal, with T cells driving tumor progression. Immunometabolism links metabolic pathways to immune responses in the tumor microenvironment.
Researchers conducted a retrospective study to explore the relationship between T cell phenotypes, circulating metabolites, and malignant brain tumors.
They used a multiple Mendelian randomization approach to examine the links between T-cell phenotypes, malignant brain tumors, and plasma metabolites. Instrumental variables were selected based on strict criteria, and various Mendelian randomization methods identified potential causal pathways and metabolites.
The results showed significant associations between 7 T cell phenotypes, including CD8+ and regulatory T cell subsets, and malignant brain tumors. About 87 plasma metabolites were correlated with these tumors, with octadecanedioylcarnitine (C18-DC) and eicosanedioate (C20-DC) modulating tumor risk. Additionally, 5-dodecenoate (12:1n7) and arachidonate (20:4n6) influenced tumor risk, particularly in relation to CD28− CD8+ T cells.
Investigators found TENS to be an effective and safe intervention for reducing pain in patients with primary trigeminal neuralgia. The evidence supported TENS as a viable option, though future research should focus on standardizing protocols and assessing long-term efficacy and safety.
Source: bmcneurol.biomedcentral.com/articles/10.1186/s12883-024-04015-1
